Agios Pharmaceuticals, Inc.

AGIO Healthcare Biotechnology

Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024.

Revenue
+330.0%
EPS
+38.8%
Free cash flow
+32.6%

Quarter to September 2026, against a year earlier

29.41 1.14 +4.03%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
3/9
Altman Z
8.12
Beneish M
−1.72
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
4 2 5 3 5 — — — 4 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 2.79 0.00
P/S ratio
24.20 64.81 28.05 24.30 14.71 — 105.92 47.37 51.15 29.21
Altman Z-Score
2.62 3.90 6.94 4.15 0.63 — 5.88 4.30 8.85 8.12
P/FCF ratio
59.03 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
1.72 (2.35) 1.17 (1.43) (4.60) — 9.11 6.45 14.71 12.52
P/Operating CF
(33.01) (37.44) (35.69) (30.60) (60.52) — (22.80) (17.53) (14.02) (16.40)
Beneish M-Score
(4.83) (2.22) (1.10) (1.57) — — — (2.43) 2.39 (1.72)
P/B ratio
4.72 7.42 3.85 4.47 7.48 — 1.37 1.57 1.21 1.32
EV/Sales
16.45 54.95 21.85 19.51 11.90 — 50.95 18.41 26.67 13.40
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
EV/FCF
40.13 (8.15) (6.62) (6.01) (7.93) — (2.31) (1.67) (2.49) (1.92)
Current Ratio
6.33 4.69 6.56 6.59 6.74 17.79 13.30 12.27 11.90 11.46
Net Debt/EBITDA
2.78 1.35 1.63 1.81 1.77 2.82 2.05 1.99 2.06 1.80
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(56.41%) (85.73%) (65.10%) (61.97%) (62.95%) 189.74% (19.37%) (36.83%) 57.29% (30.20%)
ROA
(38.20%) (51.02%) (46.99%) (47.05%) (37.55%) 140.11% (17.32%) (32.36%) 51.82% (27.89%)
ROIC
0.00% 0.00% (221.60%) (258.99%) 0.00% (86.88%) (76.54%) (717.72%) (41.11%) (87.12%)
Return on Tangible Assets
(39.95%) (83.97%) (63.54%) (74.77%) (57.12%) 155.30% (29.23%) (45.07%) 75.18% (47.41%)
Average Days of Receivables
43.42 31.14 40.38 47.42 45.62 0.00 56.54 38.24 41.09 71.46
Earnings Yield
(11.68%) (11.27%) (13.08%) (14.39%) (10.94%) — (15.40%) (27.77%) 35.88% (26.12%)
Free Cash Flow Yield
1.69% (10.40%) (11.76%) (13.36%) (10.20%) — (20.78%) (23.28%) (20.97%) (23.91%)
Free Cash Flow per Share
0.73 (6.22) (5.42) (6.38) (4.42) (6.83) (5.72) (5.31) (6.89) (6.51)
Book value per Share
9.16 8.06 11.97 10.68 5.79 21.37 20.09 14.57 27.13 20.58
Free Cash Flow
28.65 (289.86) (311.41) (382.65) (304.86) (413.06) (313.39) (295.74) (391.49) (377.29)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026